{"id":48562,"date":"2023-01-30T13:54:49","date_gmt":"2023-01-30T13:54:49","guid":{"rendered":"http:\/\/www.brandon.ddtest.info\/multisite-test\/valneva-epavla-takes-on-some-risk-with-its-use-of-debt\/"},"modified":"2023-01-30T13:54:49","modified_gmt":"2023-01-30T13:54:49","slug":"valneva-epavla-takes-on-some-risk-with-its-use-of-debt","status":"publish","type":"post","link":"http:\/\/www.brandon.ddtest.info\/multisite-test\/valneva-epavla-takes-on-some-risk-with-its-use-of-debt\/","title":{"rendered":"Valneva (EPA:VLA) Takes On Some Risk With Its Use Of Debt"},"content":{"rendered":"<p> \n<\/p>\n<div data-cy-id=\"article-content\">\n<p> The external fund manager backed by Berkshire Hathaway&#8217;s Charlie Munger, Li Lu, makes no bones about it when he says &#8216;The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.&#8217;  So it seems the smart money knows that debt &#8211; which is usually involved in bankruptcies &#8211; is a very important factor, when you assess how risky a company is.  We can see that <!-- --><strong>Valneva SE<\/strong> (<!-- --><a href=\"https:\/\/simplywall.st\/stocks\/fr\/pharmaceuticals-biotech\/epa-vla\/valneva-shares\" target=\"_blank\" rel=\"noopener noreferrer\" data-vars-link-type=\"intro\" class=\"company-report-links\">EPA:VLA<\/a>) does use debt in its business.  But the real question is whether this debt is making the company risky. <!-- --><\/p>\n<h2> When Is Debt A Problem? <\/h2>\n<p> Generally speaking, debt only becomes a real problem when a company can&#8217;t easily pay it off, either by raising capital or with its own cash flow.   If things get really bad, the lenders can take control of the business.  However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet.  Having said that, the most common situation is where a company manages its debt reasonably well &#8211; and to its own advantage.  When we think about a company&#8217;s use of debt, we first look at cash and debt together. <\/p>\n<p> <!-- --><\/p>\n<p><span class=\"veryHighlightLink\"><a href=\"https:\/\/simplywall.st\/stocks\/fr\/pharmaceuticals-biotech\/epa-vla\/valneva-shares\" target=\"_blank\" rel=\"noopener noreferrer\" data-vars-link-type=\"cta\" class=\"company-report-links\"> View our latest analysis for Valneva <\/a><\/span><\/p>\n<h2> What Is Valneva&#8217;s Net Debt? <\/h2>\n<p> You can click the graphic below for the historical numbers, but it shows that as of September 2022 Valneva had \u20ac105.9m of debt, an increase on \u20ac57.8m, over one year.    But it also has \u20ac261.0m in cash to offset that, meaning it has \u20ac155.2m net cash.  <\/p>\n<figure><a href=\"https:\/\/simplywall.st\/stocks\/fr\/pharmaceuticals-biotech\/epa-vla\/valneva-shares\/health\" target=\"_blank\" rel=\"noopener noreferrer\" data-vars-link-type=\"infographic\" class=\"company-report-links\"><img src=\"https:\/\/images.simplywall.st\/asset\/chart\/4550716-debt-equity-history-analysis-1-dark\/1675085715260\" alt=\"debt-equity-history-analysis\" width=\"821\" height=\"526\" loading=\"lazy\" class=\"styled__ChartImage-sc-ke2t77-5 febeXd\"\/><\/a><figcaption class=\"wp-caption-text\">ENXTPA:VLA Debt to Equity History January 30th 2023<\/figcaption><\/figure>\n<h2> A Look At Valneva&#8217;s Liabilities <\/h2>\n<p> According to the last reported balance sheet, Valneva had liabilities of \u20ac374.2m due within 12 months, and liabilities of \u20ac158.9m due beyond 12 months.   Offsetting this, it had \u20ac261.0m in cash and \u20ac57.7m in receivables that were due within 12 months.   So its liabilities outweigh the sum of its cash and (near-term) receivables by \u20ac214.3m.   <\/p>\n<p> This deficit isn&#8217;t so bad because Valneva is worth \u20ac890.4m, and thus could probably raise enough capital to shore up its balance sheet, if the need arose.  But we definitely want to keep our eyes open to indications that its debt is bringing too much risk.    Despite its noteworthy liabilities, Valneva boasts net cash, so it&#8217;s fair to say it does not have a heavy debt load!   <\/p>\n<p> <!-- --><\/p>\n<p> Notably, Valneva made a loss at the EBIT level, last year, but improved that to positive EBIT of \u20ac27m in the last twelve months.     When analysing debt levels, the balance sheet is the obvious place to start.  But ultimately the future profitability of the business will decide if Valneva can strengthen its balance sheet over time.  So if you&#8217;re focused on the future you can check out this <!-- --><strong>free<\/strong> <!-- --><a href=\"https:\/\/simplywall.st\/stocks\/fr\/pharmaceuticals-biotech\/epa-vla\/valneva-shares\/future\" target=\"_blank\" rel=\"noopener noreferrer\" data-vars-link-type=\"integrated-pitch\" class=\"company-report-links\">report showing analyst profit forecasts<\/a>. <!-- --><\/p>\n<p> Finally, a business needs free cash flow to pay off debt; accounting profits just don&#8217;t cut it.   Valneva may have net cash on the balance sheet, but it is still interesting to look at how well the business converts its earnings before interest and tax (EBIT) to free cash flow, because that will influence both its need for, and its capacity to manage debt.    During the last year, Valneva burned a lot of cash.  While that may be a result of expenditure for growth, it does make the debt far more risky.   <\/p>\n<p> <!-- --><\/p>\n<h2>Summing Up<\/h2>\n<p> Although Valneva&#8217;s balance sheet isn&#8217;t particularly strong, due to the total liabilities, it is clearly positive to see that it has net cash of \u20ac155.2m.      So although we see some areas for improvement, we&#8217;re not too worried about Valneva&#8217;s balance sheet.    There&#8217;s no doubt that we learn most about debt from the balance sheet.  However, not all investment risk resides within the balance sheet &#8211; far from it.   For instance, we&#8217;ve identified <!-- --><a href=\"https:\/\/simplywall.st\/stocks\/fr\/pharmaceuticals-biotech\/epa-vla\/valneva-shares\" target=\"_blank\" rel=\"noopener noreferrer\" data-vars-link-type=\"integrated-pitch\" class=\"company-report-links\"> <!-- --><strong> 3 warning signs for Valneva<\/strong> <!-- --><\/a> that you should be aware of.   <!-- --><\/p>\n<p> <!-- --><\/p>\n<p> When all is said and done, sometimes its easier to focus on companies that don&#8217;t even need debt. Readers can access a <!-- --><a href=\"https:\/\/simplywall.st\/discover\/investing-ideas\/27012\/net-cash-stocks-with-a-growth-track-record\" target=\"_blank\" rel=\"noopener noreferrer\" data-vars-link-type=\"conclusion-grid\" class=\"company-report-links\">list of growth stocks with zero net debt<\/a> <!-- --><strong>100% free<\/strong>, right now. <!-- --><\/p>\n<div class=\"styled__Box-sc-1605bki-1 jaAnUg\">\n<h3 class=\"styled__Title-sc-1605bki-2 kCXWcO\">Valuation is complex, but we&#8217;re helping make it simple.<\/h3>\n<p>Find out whether <!-- -->Valneva<!-- --> is potentially over or undervalued by checking out our comprehensive analysis, which includes<!-- --> <!-- --><strong>fair value estimates, risks and warnings, dividends, insider transactions and financial health.<\/strong><\/p>\n<p><a href=\"https:\/\/simplywall.st\/stocks\/fr\/pharmaceuticals-biotech\/epa-vla\/valneva-shares\/valuation\" target=\"_blank\" data-focus=\"dashed\" class=\"sc-crXcEl ehbMLh\" rel=\"noopener\">View the Free Analysis<\/a><\/div>\n<p class=\"styled__Feedback-sc-ke2t77-3 ihBEdD\"><strong>Have feedback on this article? Concerned about the content?<\/strong> <!-- --><a href=\"https:\/\/feedback.simplywall.st\/article\/MjM1OTkzNTo0NjM0ZDVmMmQ5YjcwMDRi\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"company-report-links\"><strong>Get in touch<\/strong><\/a><strong> with us directly.<\/strong><i> Alternatively, email editorial-team (at) simplywallst.com.<\/i><\/p>\n<p><i>This article by Simply Wall St is general in nature. <!-- --><strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.<\/strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<!-- --><\/i><\/p>\n<\/div>\n\n<br \/><a href=\"https:\/\/news.google.com\/__i\/rss\/rd\/articles\/CBMiigFodHRwczovL3NpbXBseXdhbGwuc3Qvc3RvY2tzL2ZyL3BoYXJtYWNldXRpY2Fscy1iaW90ZWNoL2VwYS12bGEvdmFsbmV2YS1zaGFyZXMvbmV3cy92YWxuZXZhLWVwYXZsYS10YWtlcy1vbi1zb21lLXJpc2std2l0aC1pdHMtdXNlLW9mLWRlYnTSAY4BaHR0cHM6Ly9zaW1wbHl3YWxsLnN0L3N0b2Nrcy9mci9waGFybWFjZXV0aWNhbHMtYmlvdGVjaC9lcGEtdmxhL3ZhbG5ldmEtc2hhcmVzL25ld3MvdmFsbmV2YS1lcGF2bGEtdGFrZXMtb24tc29tZS1yaXNrLXdpdGgtaXRzLXVzZS1vZi1kZWJ0L2FtcA?oc=5\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The external fund manager backed by Berkshire Hathaway&#8217;s Charlie Munger, Li Lu, makes no bones about it when he says &#8216;The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.&#8217; So it seems the smart money knows that debt &#8211; which is usually involved in &hellip;<\/p>\n","protected":false},"author":1,"featured_media":48563,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[161],"tags":[],"_links":{"self":[{"href":"http:\/\/www.brandon.ddtest.info\/multisite-test\/wp-json\/wp\/v2\/posts\/48562"}],"collection":[{"href":"http:\/\/www.brandon.ddtest.info\/multisite-test\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.brandon.ddtest.info\/multisite-test\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.brandon.ddtest.info\/multisite-test\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.brandon.ddtest.info\/multisite-test\/wp-json\/wp\/v2\/comments?post=48562"}],"version-history":[{"count":0,"href":"http:\/\/www.brandon.ddtest.info\/multisite-test\/wp-json\/wp\/v2\/posts\/48562\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.brandon.ddtest.info\/multisite-test\/wp-json\/wp\/v2\/media\/48563"}],"wp:attachment":[{"href":"http:\/\/www.brandon.ddtest.info\/multisite-test\/wp-json\/wp\/v2\/media?parent=48562"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.brandon.ddtest.info\/multisite-test\/wp-json\/wp\/v2\/categories?post=48562"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.brandon.ddtest.info\/multisite-test\/wp-json\/wp\/v2\/tags?post=48562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}